CELL INTELLIGENCE · 肿瘤细胞治疗研究

探索 CAR-T 之外的 CAR 细胞疗法用于髓系恶性肿瘤

Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.

异基因移植后急性髓系白血病复发中重编程失败的移植物抗白血病免疫的研究进展

Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation.

丙戊酸增强 CAR-T 细胞对急性髓系白血病的细胞毒性

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.

AML 中的 CAR-T 与 CAR-NK 细胞疗法：打破壁垒，规划未来

CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future.

脐带血来源 CAR-NK 细胞：肿瘤免疫治疗的新兴即用型平台

Umbilical cord blood-derived CAR-NK cells: an emerging off-the-shelf platform for cancer immunotherapy.

CAR-T 治疗急性髓系白血病的临床前进展与机制见解：从靶点迭代到微环境调控

Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.

本综述系统总结了 CAR-T 疗法治疗 AML 的临床前进展及机制基础，聚焦于两大核心瓶颈。

儿童和青少年癌症患者 CAR-T 细胞药物研发儿科战略论坛：ACCELERATE 与欧洲药品管理局合作、美国食品药品监督管理局参与

Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i

CAR-T 与 CAR NK 细胞治疗急性髓系白血病的最新进展

Recent advances in CAR T and CAR NK cell therapy for AML.

FLT3 突变白血病干细胞：耐药机制与新的治疗靶点

FLT3-Mutated Leukemic Stem Cells: Mechanisms of Resistance and New Therapeutic Targets.

靶向 CD123 和 CLL1 的双顺反子 CAR-T 细胞用于降低 AML 抗原逃逸风险

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape.

靶向 CD123 和 CLL1 的双顺反子 CAR-T 细胞可能是治疗 AML 的一种有用且安全的方法。